Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Esophageal
Advertisement
We recently spoke with expert clinicians about the rapidly changing treatment landscape in upper gastrointestinal cancers.
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
Pembro plus lenvatinib with chemo may improve progression-free survival in patients when compared with the standard of care.
Researchers define characteristics of e-GISTS and determine whether endoscopic resection is a treatment option for patients.
Palliative EBRT can reduce physician-evaluated and patient-reported dysphagia symptoms in patients with incurable disease.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Dr. Cytryn shares insights on the implications of recent data from the DESTINY-Gastric04 and MATTERHORN trials.
The approval is based on positive results from the phase III RATIONALE-306 study.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.